

# **Amendment Statement of Principles concerning**

## MALIGNANT NEOPLASM OF THE EYE (Balance of Probabilities)

(No. 20 of 2020)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(3) and (8) of the *Veterans' Entitlements Act* 1986.

Dated 28 February 2020

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO

Chairperson

### Contents

1	Name	3
2	Commencement	3
3	Authority	3
4	Amendment	3

#### 1 Name

This is the Amendment Statement of Principles concerning *malignant* neoplasm of the eye (Balance of Probabilities) (No. 20 of 2020).

#### 2 Commencement

This instrument commences on 23 March 2020.

#### 3 Authority

This instrument is made under subsections 196B(3) and (8) of the *Veterans' Entitlements Act 1986*.

#### 4 Amendment

The Statement of Principles concerning *malignant neoplasm of the eye* (*Balance of Probabilities*) (No. 28 of 2018) (Federal Register of Legislation No. F2018L00197) is amended in the following manner:

Section	Amendment
9(4)	Replace the existing factor in subsection 9(4) with the following:
	being treated with an immunosuppressive drug:
	(a) for a cumulative period of at least three months before the clinical onset of malignant neoplasm of the eye; and
	(b) where the first treatment occurred at least five years before the clinical onset of malignant neoplasm of the eye; and
	(c) where that exposure has ceased, the clinical onset of malignant neoplasm of the eye has occurred within ten years of cessation;
	Note: <i>immunosuppressive drug</i> is defined in the Schedule 1 - Dictionary.
Schedule 1 – Dictionary	Replace the existing definition of "immunosuppressive drug" with the following:
	<i>immunosuppressive drug</i> means a drug or an agent which results in substantial suppression of immune responses.
	<ul> <li>Note: Examples of an immunosuppressive drug include, but are not limited to:</li> <li>(a) chemotherapeutic agents used for the treatment of cancer;</li> <li>(b) corticosteroids, other than inhaled or topical corticosteroids;</li> <li>(c) drugs used to prevent transplant rejection; and</li> <li>(d) tumour necrosis factor-α inhibitors.</li> </ul>